GoodRx Q1 revenue beats estimates but declines 4.4% year on year

Earnings
โดย StockStory·Read original
Summary · why it matters

GoodRx reported first-quarter revenues of $194 million, down 4.4% year on year, exceeding analysts' expectations by 4.9%. The company also provided full-year revenue guidance that slightly topped estimates. Among the seven healthcare technology stocks tracked, GoodRx posted the slowest revenue growth, while the group overall beat consensus revenue estimates by 1.6% and issued in-line next-quarter guidance. Omnicell delivered the best performance with revenues of $309.9 million, up 14.9% year on year, and Hims & Hers Health was the weakest, with revenues of $608.1 million missing estimates by 1.4%. Astrana Health achieved the fastest revenue growth at 55.6% year on year, and Tandem Diabetes raised its full-year guidance the most among peers.

Impact on stocks 5

Health Care± Mixed · 3 stocks
Goodrx Holdings Inc
GDRX
▼ NegativeDemandrelevance

Revenue declined 4.4% year on year, the slowest among peers, indicating weak demand.

Hims Hers Health Inc
HIMS
▼ NegativeDemandrelevance

Revenue missed estimates by 1.4%, indicating weaker-than-expected demand.

Omnicell Inc
OMCL
▲ PositiveDemandrelevance

Revenue grew 14.9% year on year, the best performance among peers, indicating strong demand.

Biotech & Genomic Medicine▲ · 1 stocks
Aging Population▲ · 1 stocks
Astrana Health Inc
ASTH
▲ PositiveDemandrelevance

Astrana Health achieved the fastest revenue growth at 55.6% year on year, indicating strong demand.

© 2026 MarketDXNews